Monday, November 08, 2010
Among the deals it cited:
-Boeing, headquartered in Chicago, would sell 10 C-17 Globemaster III military transport aircraft to the Indian Air Force. The deal, if finalized, would make India the operator of the largest fleet of C-17s outside of the United States. 22,160 jobs.
-Boeing, 30 B737-800 commercial aircraft to India's SpiceJet. 12,970 jobs.
-General Electric, headquartered in Fairfield, Conn., 107 F414 engines for light combat aircraft. 4,440 jobs.
-Bucyrus International, South Milwaukee, Wis., mining equipment and services to support a coal-fired power plant in Madhya Pradesh, India. 3,460 jobs.
-GE, six advanced class 9FA gas turbines and three steam turbines for the 2,500-megawatt Samalkot power plant expansion for Reliance Power Ltd. The turbines are assembled in Greenville, S.C. 2,650 jobs.
-Robbins Co., of Solon, Ohio, tunnel-boring equipment for a water project in Mumbai. 35 jobs.
-Spancrete Machinery Corp. of Waukesha, Wis., sales of six sets of production equipment. 30 jobs.
-Implant Sciences, Wilmington, Mass., devices to detect bomb-making materials. 30 jobs.
-SPX Communication Technology, Raymond, Maine, pilot deployment of long-range mobile phone antenna system. 5 jobs.
Other India deals for which the Obama administration did not provide job numbers:
-Bell Helicopter, Hurst, Texas, on Aug. 25 sold its first Bell Model 429 corporate VIP helicopter in India to Span Air, a private air charter company. Bell Helicopter recently sold its 100th helicopter in India, the administration said.
-Duke Medicine, located in Durham, N.C., entered into a joint venture with Medanta Medicity, a hospital and medical research complex, to launch a clinical research facility within Medanta's hospital. Duke Medicine will provide scientific and operational leadership, while Medanta will contribute financial resources and clinical and operational services.
Duke Medicine also will be partnering with Jubilant Life Sciences, headquartered in Uttar Pradesh, to conduct research studies and co-develop promising discoveries, with significant funding and in-kind support provided by Jubilant. Subsequent commercialization is expected to result in licensing revenue for Duke Medicine.